Despite randomized controlled trial data supporting the use of selective estrogen receptor modulators (SERMs) to reduce the incidence of breast cancer, to the authors' knowledge uptake has been limited. Similar to cardiovascular risk models, the routine use of breast cancer risk prevention models in the clinical setting to identify those patients at highest risk of developing breast cancer can maximize the risk-benefit ratio of SERMs and provide an impetus to move forward with implementing breast cancer prevention.

Original languageEnglish
Pages (from-to)2387-2391
Number of pages5
Issue number12
StatePublished - Jun 15 2007


Dive into the research topics of 'Moving forward with breast cancer prevention'. Together they form a unique fingerprint.

Cite this